ReviewAddiction biology2008
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
Review in Addiction biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06218056 (Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use), which is not on this map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Clinical correlates of co-occurring cannabis and tobacco use: a systematic review.Addiction (Abingdon, England) · 2012Pooled it
- Cannabinoid type 1 receptor antagonists for smoking cessation.The Cochrane database of systematic reviews · 2011Pooled it
- THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction.Translational psychiatry · 2013Trial
- Antagonist-elicited cannabis withdrawal in humans.Journal of clinical psychopharmacology · 2011Trial
- Randomized, controlled, double-blind trial of taranabant for smoking cessation.Psychopharmacology · 2010Trial
- Article
- Nicotine and neuronal nicotinic acetylcholine receptors: unraveling the mechanisms of nicotine addiction.Frontiers in neuroscience · 2025Review
- Nicotine replacement therapy: insights into the mechanisms and potential of nicotine receptor pathway.American journal of translational research · 2025Review
- Adult consequences of repeated nicotine and ΔPsychopharmacology · 2024Article
- Neurobiology of Stress-Induced Nicotine Relapse.International journal of molecular sciences · 2024Review
- Anxiety Modulation by Cannabinoids-The Role of Stress Responses and Coping.International journal of molecular sciences · 2023Review
- Differential roles of diacylglycerol lipase (DAGL) enzymes in nicotine withdrawal.Brain research · 2023Article
- Fatty Acid-Binding Protein 5 Gene Deletion Enhances Nicotine-Conditioned Place Preference: Illuminating the Putative Gateway Mechanisms.Future pharmacology · 2023Article
- Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach.International journal of environmental research and public health · 2023Article
- Tobacco and nicotine use.Nature reviews. Disease primers · 2022Review
- CB2 Receptor Involvement in the Treatment of Substance Use Disorders.Biomolecules · 2021Review
- Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.International journal of obesity (2005) · 2020Review
- Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice.Neuropharmacology · 2020Article
- Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co- and tri-use.Drug and alcohol dependence · 2019Article
- Among whom is cigarette smoking declining in the United States? The impact of cannabis use status, 2002-2015.Drug and alcohol dependence · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Tobacco use is one of the leading preventable causes of death in developed countries. Since existing medications are only partially effective in treating tobacco smokers, there is a great need for improved medications for smoking cessation. It has been recently proposed that cannabinoid CB(1) receptor antagonists represent a new class of therapeutic agents for drug dependence, and notably, nicotine dependence. Here, we will review current evidence supporting the use of this class of drugs for smoking cessation treatment. Pre-clinical studies indicate that nicotine exposure produces changes in endocannabinoid content in the brain. In experimental animals, N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (rimonabant, SR141716) and N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), two cannabinoid CB(1) receptor antagonists, block nicotine self-administration behavior, an effect that may be related to the blockade of the dopamine-releasing effects of nicotine in the brain. Rimonabant also seems efficacious in decreasing the influence of nicotine-associated stimuli over behavior, suggesting that it may act on two distinct neuronal pathways, those implicated in drug-taking behavior and those involved in relapse phenomena. The utility of rimonabant has been evaluated in several clinical trials. It seems that rimonabant is an efficacious treatment for smoking cessation, although its efficacy does not exceed that of nicotine-replacement therapy and its use may be limited by emotional side effects (nausea, anxiety and depression, mostly). Rimonabant also appears to decrease relapse rates in smokers. These findings indicate significant, but limited, utility of rimonabant for smoking cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.